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Thalidomide-Induced Teratogenesis: History and Mechanisms
Neil Vargesson
Nearly 60 years ago thalidomide was prescribed to treat morning sickness in
pregnant women. What followed was the biggest man-made medical disaster
ever, where over 10,000 children were born with a range of severe and
debilitating malformations. Despite this, the drug is now used successfully to
treat a range of adult conditions, including multiple myeloma and
complications of leprosy. Tragically, a new generation of thalidomide damaged
children has been identified in Brazil. Yet, how thalidomide caused its
devastating effects in the forming embryo remains unclear. However, studies
in the past few years have greatly enhanced our understanding of the
molecular mechanisms the drug. This review will look at the history of the
drug, and the range and type of damage the drug caused, and outline the
mechanisms of action the drug uses including recent molecular advances
and new findings. Some of the remaining challenges facing thalidomide
biologists are also discussed.
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Part one: History and Thalidomide Embryopathy
Thalidomide was released in the late 1950’s as a nonaddic-
tive, nonbarbiturate sedative by the German pharmaceutical
company, Chemie-Grunenthal (Fig. 1). Thalidomide was very
effective and quickly discovered to also be an effective anti-
emetic and used to treat morning sickness in pregnant
women. Thalidomide was marketed and distributed in 46
countries around the world using different names. For
example, the drug was known as Distaval in the UK and
Australia, but was called Softenon in Europe and Contergan
in Germany (Vargesson, 2009, 2013). Thalidomide became
one of the world’s largest selling drugs, and was marketed
heavily and advertised as completely safe (Vargesson, 2009;
Fig. 1B) right up until it was eventually banned in Novem-
ber, 1961. Indeed, sample packets of the drug were given
out to physicians to distribute freely to patients suffering
from morning sickness (Fig. 1B). Precisely how many
women were given the drug will never be known.
Soon after thalidomide’s release, reports surfaced of
patients developing peripheral neuropathy after taking the
drug. Reports of occurrences of severe birth defects affect-
ing multiple body systems were also coming to light, that
initially were not linked to, or were denied to be due to
thalidomide. It was not until 1961 that thalidomide was
confirmed by two independent clinicians, Lenz in Germany
and McBride in Australia, to be the cause of the largest
man-made medical disaster in history (McBride, 1961;
Lenz, 1962) with huge numbers (over 10,000) of severe
birth defects in children. In addition, there were reports of
increased miscarriage rates during this period (Lenz, 1988;
Vargesson, 2009, 2013; McCredie, 2009; Stephens, 2009).
Thalidomide was subsequently withdrawn from the UK
in Nov 1961 and by 1962 from most of the world. As a
result, the incidence and occurrence of these severe birth
defects was then not seen.
Whether this disaster could have been prevented
remains unclear. The packaging and information of contrain-
dications of drugs was minimal when compared to the way
drugs are sold today (Fig. 1B). More importantly, the state
of drug testing in the 1950s and 1960s was different when
compared to today’s standards. According to Grunenthal, the
testing of thalidomide was carried out using the standards
of the time (http://www.contergan.grunenthal.info/grt-ctg/
GRT-CTG/Die_Fakten/FAQ/152700081.jsp). It remains a mat-
ter of contention/debate as to precisely what testing was
carried out and, as importantly, when Grunenthal became
aware of thalidomide being a human teratogen and whether
the disaster could have been prevented sooner.
Thalidomide was not approved or licensed for use in
the USA between 1957 and 1962, despite pressure to do
so. An FDA physician, Frances Kelsey, responsible for
approving drug licenses, had concerns about the safety of
the drug, given the reports of peripheral neuropathy in
patients taking the drug, but was also concerned about
effects during pregnancy. Dr Kelsey was subsequently
awarded the President’s Award for Distinguished Federal
Civilian Service by President John F. Kennedy for averting a
thalidomide disaster in the USA (Vargesson, 2009, 2013).
The thalidomide disaster completely changed the way
drugs are tested. In fact, articles written by Dr Frances
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Kelsey provided the foundation for modern day drug test-
ing (Kelsey, 1988; Vargesson, 2013). Moreover, the thalido-
mide disaster demonstrated for the first time that species
differences exist in drug reaction/response. Mice, tradi-
tionally used to screen for drug action, are less sensitive
to thalidomide than other species like non-human prima-
tes, rabbits, etc. (Merker et al., 1988; Stephens et al., 2000;
Vargesson, 2013). Why mice are less sensitive to the drug
remains unclear. Since the disaster, drug screening policies
have changed to incorporate several species as well as in
vitro tests, and there has not been a repeat of the disaster.
The evidence that thalidomide causes birth defects is now
undoubted. Multiple animal species have been shown to be
susceptible to thalidomide damage, including non-human pri-
mates, rabbits, armadillos, Xenopus, marsupials, hamster,
chicken, zebrafish, marine fish, hydra, and even bacteria (Fort
et al., 2000; Vargesson, 2013; Hartmann et al., 2014). The tha-
lidomide disaster of 1957-61 highlighted, for the first time,
that species differences do exist in the reaction to drugs.
Oddly, no individual nor Grunenthal itself was success-
fully prosecuted over the disaster. There are reports that
Grunenthal may have entered into an agreement with the
German Government and the German Federal Prosecutors
offices to withdraw a criminal prosecution against them
(http://www.theguardian.com/society/2014/nov/14/-sp-
thalidomide-pill-how-evaded-justice). It took until 2012
before Grunenthal finally offered an “apology,” but stopped
short of admitting liability, yet little compensation has yet
been paid to thalidomide damaged survivors outside Ger-
many (http://www.contergan.grunenthal.info/grt-ctg/GRT-
CTG/Stellungnahme/Rede_anlaesslich_Einweihung_des_Con-
tergan-Denkmals/224600963.jsp). Grunenthal no longer
produces thalidomide, but today is one of the world’s larg-
est Pharmaceutical companies producing drugs for pain
relief.
The survivors of the thalidomide disaster have severe
handicaps, and many of the survivors are experiencing
early onset age related issues, such as osteoarthritis, joint
mobility issues and coronary heart disease, making life
more difficult (Miller and Stromland, 1999; Newman,
1999; Smithells and Newman, 1999; McCredie, 2009; Var-
gesson, 2009, 2013). In some countries the distributors of
the drug, for example, Distillers in the UK and Australia
(now Diageo), have been sued for compensation by the
FIGURE 1. Structure of thalidomide enantiomers and packaging. A: Thalidomide is a stereo-isomer and can exist in two enantiomeric states, depending on the
state of the chiral carbon (see asterisk) allowing each form to have slightly different structural moieties. Both enantiomers, R and S, can rapidly interconvert (race-
mize) in body fluids and tissues and form equal concentrations of each form. B: Thalidomide was sold/distributed as a racemic mix of both enantiomers and
called “Distaval” in the UK. These images are from an actual packet of “Distaval,” which was a Physician’s Sample and given to women in early pregnancy.
Note the safety advice on the packet. Reproduced from Vargesson, BioEssays, 2009,31,1327–1336.
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survivors. Compensation has been received from such dis-
tributors. In addition Government support has been given
to survivors. However the amount of support varies
between countries.
Today, thalidomide is used to successfully treat a
wide range of medical conditions, which include leprosy,
multiple myeloma, and cancers, as well as Crohn’s dis-
ease, HIV, and others. Thalidomide use is carefully moni-
tored using successful schemes like the S.T.E.P.S. (System
for Thalidomide Education and Prescribing Safety_pro-
gram (Zeldis et al., 1999; Uhl et al., 2006), which moni-
tors patients to ensure they are not pregnant while
receiving treatment.
However, tragically a new generation of thalidomide
survivors has occurred in Brazil (Castilla et al., 1996;
Schuler-Faccini et al., 2007; Vianna et al., 2013). Thalido-
mide is used to treat complications of leprosy in Brazil,
which is sadly common and debilitating. Unfortunately the
drug is given to patients who share the medicine with
others, and who do not understand or are not informed of
the dangers, and damaged children are born. The damage
to these children is similar to the damage seen in children
between 1957 and 1962.
Thalidomide Embryopathy
Between 1957 and 1962, thalidomide caused severe birth
defects in over 10,000 children. Almost any tissue/organ
could be affected by thalidomide. Indeed a detailed UK
Government sponsored report in 1964 (UK Government
Report, 1964) detailed that almost all the tissues and
organs of the body could be affected by the drug. Some
hallmark/consistent features were identified by German,
UK, and also Australian physicians (Lenz and Knapp,
1962; Smithells, 1962; Spiers, 1962; Taussig, 1962; Now-
ack, 1965; Smithells, 1973; McBride, 1976; Ruffing, 1977;
Newman, 1985; Newman, 1986; Smithells and Newman,
1992; McCredie, 2009). Damage was primarily seen to the
limbs (upper limbs more commonly affected than lower
limbs), face, eyes, ears, genitalia, and internal organs,
including heart, kidney, and gastrointestinal tract. The ver-
tebral column was also affected in some survivors and
occurrence of facial palsies was also documented.
Due to the wide range of damage and conditions that
thalidomide exposure can cause, the damage is usually
referred to collectively as thalidomide embryopathy or tha-
lidomide syndrome, as some of the damage is not unique
to thalidomide embryopathy and can be seen in other
human conditions, for example Duane syndrome (Smithells
and Newman 1992; Miller and Stromland, 1999). Thalido-
mide embryopathy is a severe condition and affects many
tissues, all of which can occur independently in humans
but rarely together.
Infant mortality in babies born with severe thalidomide
embryopathy is as high as 40%, quite likely due to inter-
nal organ damage (Smithells and Newman, 1992; Varges-
son, 2013). Furthermore, many babies with these
malformations are likely to have died in utero and been
miscarried or stillborn. The true numbers of babies
affected by thalidomide will likely never be known.
The hallmarks/consistent features of thalidomide
embryopathy were identified by examining the most
severely affected children to determine a diagnostic crite-
ria, which is still used today (Smithells and Newman,
1992). Recently the diagnostic criteria was re-examined
following a World Health Organization sponsored Advisory
Panel and a new, broader diagnostic system has been sug-
gested (www.who-umc.org/graphics/28280.pdf) .
LIMB DEFECTS
Damage to the limbs are one of the most common and
studied features of thalidomide embryopathy.
Upper limb. Phocomelia remains the most striking limb
deformity caused by thalidomide, and remains the stereo-
typical image of thalidomide embryopathy. Phocomelia
occurs through a severe shortening of the limb/s, due to
proximal elements (long bones) being reduced or missing
and leaving distal elements (handplate) in place. Phocome-
lia ranges in severity, from severe, where long bones are
missing with just a flipper-like structure consisting of dig-
its/handplate articulating with the body, to less severe
forms exhibiting a shortening of the long bones and nor-
mal distal bones. Radial dysplasia (loss of the radius and
thumb) is also seen in thalidomide survivors (Lenz and
Knapp, 1962; Spiers, 1962; Taussig, 1962; Ruffing, 1977;
Smithells, 1973; Newman, 1985; Smithells and Newman,
1992). The range and type of upper limb deformities
induced by thalidomide exposure exhibit a characteristic
pattern. The thumb is the first structure to be affected, fol-
lowed by the radius, humerus, and lastly the ulna (Lenz
and Knapp, 1962; Nowack, 1965; Smithells and Newman,
1992; McCredie, 2009; Miller et al., 2009). The majority of
thalidomide survivors exhibit some form of limb deformity,
which are usually reduction defects and most often sym-
metrical. Indeed symmetrical limb defects remain one of
the hallmarks for the diagnosis of thalidomide embryop-
athy. However, several studies indicate that unilateral limb
defects can occur in thalidomide survivors and differences
in severity can also occur between each side of the
body—so does not have to be symmetrical (Lenz and
Knapp, 1962; UK Government Report, 1964; Schmidt and
Salzano, 1980; Schmidt and Salzano, 1983).
Lower limb. The lower limbs can also exhibit thalidomide-
induced damage. Phocomelia or Amelia are seen, as well
as reduction in the long bone lengths. However, abnormal-
ities of the lower limbs are seen less commonly than those
of the upper limbs, with lower limb deformities on their
own occurring, but being very rare. The femur is the bone
most often affected in the lower limb, and similarly to the
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ulna, the fibula is usually the final bone to remain normal
(Nowack, 1965; Hamanishi, 1980; Lenz, 1988; Smithells
and Newman, 1992; Miller and Stromland, 1999; McCre-
die, 2009).
Polydactyly (extra digits) was also observed in hands
and/or feet of thalidomide survivors in reduced limbs, as
well as in combination with phocomelia (UK Government
Report, 1964; McBride, 1961; Smithells and Newman,
1992; Vianna et al., 2013). The ability of thalidomide to
cause severe limb reduction or loss of proximal elements,
but to then duplicate distal digits, adds to the mystery of
thalidomide-induced embryopathy.
Why the upper limbs are more affected in thalidomide
survivors is unclear. We do know the lower limbs form
slightly after upper limbs, and we know that thalidomide
has a short half-life of activity, thus it is possible a single
dose in the early stages of pregnancy could affect the
upper limbs, whereas multiple doses over a few days may
be required to affect the later forming lower limbs.
The severity of limb damage seen in thalidomide survi-
vors can vary between each side of individuals. Some cases
exhibit bilateral disorders and others have a more severely
affected limb on one side of the body. More strikingly, there
are several reports of unilateral limb damage in thalidomide
survivors, though these cases are rare (Lenz and Knapp,
1962; Somers, 1962; UK Government Report, 1964; Schmidt
and Salzano, 1980; Schmidt and Salzano, 1983).
SHOULDER AND HIP JOINTS
Characteristic shoulder and hip joint damage occurs in
thalidomide embryopathy. For example, the acromioclavic-
ular joint of the shoulder is more prominent, and sharp-
ened in appearance, when the shoulder is damaged
through thalidomide exposure (Newman, 1977). The hip
joint can be hypoplastic or, in some cases, completely
absent, as is also true for the pubic bone (Newman, 1977).
EYE AND EAR DAMAGE
Eye and ear damage (internal and external) is another hall-
mark used to diagnose thalidomide embryopathy. Eyes and
ears develop in the embryo from week 4/5 until around
week 8/9, which is around the same time the limbs are
rapidly growing. Thalidomide can cause small eyes (micro-
pthalmia), anophthalmos (absence of the eyeball), and poor
vision. Eye defects also include aberrant or no lacrimation
(tear formation), coloboma, and strabismus (Smithells,
1962; Cullen, 1964; James, 1965; Newman, 1977; Schmidt
and Salzano, 1980; Kelsey, 1988; Miller and Stromland,
2011). Ocular defects can occur unilaterally, although there
may still be poor vision in the unaffected eye (Smithells,
1962). Abnormalities in eye movement are also observed
and usually occur in conjunction with ear defects and facial
muscle weakness (Smithells and Newman, 1992).
Ear defects in thalidomide survivors are usually sym-
metrical, ranging from absence of the outer (anotia) to
reduction of the outer ear (microtia; Ruffing, 1977; Smi-
thells and Newman, 1992). Deafness or reduced hearing,
as well as cranial nerve palsies in addition to ear defects,
are also observed in some thalidomide survivors (Smi-
thells and Leck, 1963; Livingstone, 1965; Newman, 1977;
Ruffing, 1977; Newman, 1985; Miller and Stromland,
1999).
FACIAL DAMAGE
Another key hallmark of thalidomide embryopathy is the
presence of an enlarged nevus or hemangioma at birth
(also known as a “storkmark”; Lenz and Knapp, 1962;
Lenz, 1988; Smithells and Newman, 1992; McCredie,
2009; Stephens, 2009). The hemangioma is usually
observed in the centre of the forehead and can extend
over the nose to the upper lip. This is a capillary hemangi-
oma and is temporary, and usually disappears within 2-3
years of birth (Newman, 1985, 1986; Smithells and New-
man, 1992). Facial palsy and facial asymmetry are also
associated with thalidomide embryopathy, likely due to
weakened facial muscles and facial nerve damage (New-
man, 1985, 1986; Smithells and Newman, 1992; Miller
and Stromland, 1999). Other facial problems linked to tha-
lidomide damage include irregular teeth numbers/spacing,
small jaws, cleft palate and cleft lip, and small noses
(Newman, 1985, 1986; Smithells and Newman, 1992).
VERTEBRAL COLUMN
Various vertebral column issues have been reported in
thalidomide survivors, including irregular vertebral spacing;
fusion of vertebrae particularly in the lower spinal column,
and in some cases progressive kyphosis which often requires
surgical intervention throughout life (Ruffing, 1977;
Smithells and Newman, 1992). Thalidomide survivors can
have shorter stature than average, with the shortness due to
shorter leg bones, independent of vertebral defects (Brook
et al., 1977; Ruffing, 1977; Newman, 1985; Smithells and
Newman, 1992).
INTERNAL ORGAN DAMAGE
All of the internal organs can be affected following thalido-
mide exposure in utero. Damage seen includes malforma-
tions of the heart, kidneys, genitals, and gastrointestinal
tract (Smithells and Newman, 1992; Ruffing, 1977; Lenz
and Knapp, 1962). However, the precise incidence of such
deformities is unknown, as such defects are not always
outwardly seen or apparent, particularly if they do not
present until later in life.
Defects of the heart are likely the cause for many of
the intrauterine and post-natal deaths. Urinary tract and
kidneys also exhibit a range of life-threatening conditions,
including horseshoe, hypoplastic, rotated, and ectopic mal-
formations (Nowack 1965; Newman, 1985, 1986; Smithells
and Newman, 1992). Genital defects, both internal and
external, have been reported in thalidomide survivors.
These include absence of the testes, testicular
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abnormalities, and hypospadiasis in males, and in females
malformations of the uterus and reproductive tract defects
(Cuthbert and Speirs, 1963; Newman, 1985; Newman,
1986; Smithells and Newman, 1992). Other common prob-
lems associated with thalidomide exposure include anorec-
tal stenosis, intestinal atresia, pyloric stenosis, and
inguinal hernia (Lenz and Knapp, 1962; Somers, 1962;
Cuthbert and Speirs, 1963; Nowack, 1965; Newman, 1985,
1986; Smithells and Newman, 1992)
NERVE AND CNS DAMAGE
There is evidence that some thalidomide-damaged children
have facial palsies, cranial nerve conduction problems, and
an increased incidence of autism and epilepsy, which is
only diagnosed later life (Soules, 1966; Smithells and New-
man, 1992; Miller and Stromland, 1999; Miller et al.,
2005). Thalidomide could affect developing neural path-
ways (Miller and Stromland, 1999), possibly by preventing
angiogenesis in the brain (Hallene et al., 2006), resulting
in cell death and loss of tissue. Animal model evidence
indicates such damage can occur quite late in fetal devel-
opment (Hallene et al., 2006).
When Does Thalidomide Cause Damage to the
Embryo?
Thalidomide causes damage to the forming embryo in a
short time sensitive window also known as the “critical
period.” The time sensitive window extends between days
20 and days 36 after fertilization (34–50 days after last
menstrual cycle; Fig. 2; Lenz and Knapp, 1962; Nowack,
1965; Smithells and Newman, 1992; Miller and Stromland,
1999). Exposure before and after this time sensitive win-
dow is thought to not cause damage to the embryo (New-
man, 1985, 1986; Lenz and Knapp, 1962; Smithells and
Newman, 1992). However, early exposure to thalidomide
in humans and rats induces miscarriage, and late fetal
exposure in rats induces brain damage (James, 1965; Kajii
et al., 1973). This indicates there is likely no safe time
period to take the drug.
Reports indicate that a single 50 mg tablet of thalido-
mide during the time-sensitive window is sufficient to
cause birth defects in up to 50% of pregnancies. Some
reports go even further and suggest it would be surprising
if any embryo exposed to thalidomide during the time-
sensitive window was unharmed (Newman, 1985; Strom-
land and Miller, 1992; Smithells and Newman, 1992).
Indeed a detailed 1964 UK Government report into the
thalidomide disaster in the UK indicates that a few chil-
dren were born unharmed or without outward damage to
mothers with confirmed exposure to the drug during preg-
nancy (UK Government Report, 1964). Whether these indi-
viduals had other problems, not obvious at birth, that
became apparent later in life is unknown.
The time-sensitive window of thalidomide teratogenic-
ity was determined following interviews with parents of
thalidomide affected children and their doctors (Lenz and
Knapp, 1962; Nowack, 1965; Ruffing, 1977; Lenz, 1988;
Miller and Stromland, 1999; McCredie, 2009). From these
interviews, dates of intake and exposure were ascertained
and correlated to the damage seen in the infants, to deter-
mine the timing of damage. This window correlates with
outward damage primarily and severe internal organ dam-
age. Obviously any other damage that may not present
until later in life could not be recorded. Exposure to thali-
domide earlier in the time sensitive window results in
more severe damage, as evidenced by outward signs, such
as effects on the limbs, face, and genitals, and obvious
internal damage, such as kidney failure (Fig. 2). Exposure
towards the end of the window results in injuries to digits
and/or eyes/ears.
The time-sensitive window is concomitant with the
period of rapid embryonic development (from 4 weeks
onwards) with a lot of cell movement, proliferation, organo-
genesis blood vessel formation to allow all the organ and
tissue development and also many different signaling path-
ways being active. Embryogenesis lasts until around week
10–11 when the embryo is fully patterned and formed. The
remaining period of pregnancy allows the fetus, as it is now
termed, to grow and mature. As thalidomide was used to
treat morning sickness, which can occur from week 4 and
last until week 12 in some women, and in others through-
out pregnancy, this exposure coincides with the major
developmental events underpinning the thalidomide
disaster.
Given that the majority of studies in humans in the
1960’s assessed damage in severely affected infants, and
there are very few studies assessing the damage or late
onset damage in adults, it is possible that the drug did
cause far more damage than initially described.
Animal studies, particularly in nonhuman primates,
show that following thalidomide exposure a range of dam-
age is induced, which can vary between each of the litter-
mates (Merker et al., 1988; Ema et al., 2010; Vargesson,
2013). For example, one littermate could exhibit varying
damage to all 4 limbs, another to one limb, and another
just a tail anomaly (Merker et al., 1988; Ema et al., 2010;
Vargesson, 2013). The mechanism underlying this variance
in damage is unknown, but also hints that thalidomide
damage in humans could be broader.
Thalidomide-Induced Damage Can Phenocopy
some other Human Conditions
The damage thalidomide causes can vary widely between
individuals (Lenz and Knapp, 1962; UK Government
Report, 1964; Ruffing, 1977; Schmidt and Salzano, 1983;
Smithells and Newman, 1992). How and why the drug
caused such a range and variability in damage remains
unclear, but likely includes individual differences in metab-
olism and clearance of the drug, as well genetic and envi-
ronmental factors.
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Some of the thalidomide induced damage is not unique
to thalidomide embryopathy, but can be seen independ-
ently in other human conditions, such as facial palsies,
Duane syndrome, and autism and limb reduction, for
example, radial dysplasia (Smithells and Newman, 1992;
Miller and Stromland, 1999; Lenz and Knapp, 1962).
Indeed, some of the damage the drug causes can often be
confused for other human congenital malformations. This
can make diagnosis challenging on occasion, particularly if
the mother cannot recall or admit to using thalidomide
during pregnancy. For example, both Okihiro Syndrome,
characterized by limb reduction anomalies and Holt-Oram
Syndrome, typically presenting with heart and limb reduc-
tion deficiencies, can vary in severity and have been con-
fused with thalidomide embryopathy (Kohlhase et al.,
2003; Kohlhase and Holmes, 2004; Vargesson, 2013). As
has another much rarer condition, Roberts Syndrome, also
known as pseudothalidomide syndrome, given its striking
phocomelia to all four limbs, facial damage, and internal
organ damage. Roberts Syndrome is caused by a mutation
in ESCO2, a gene involved in chromosome separation, cell
division, and DNA repair (Bates, 2001; Schule et al., 2005;
Vega et al., 2005; Whelan et al., 2012). A zebrafish model
of Roberts syndrome indicates that ESCO2 loss prevents
normal development by disrupting the cell cycle (Monnich
et al., 2011). Finally, tetra-amelia occurs in thalidomide
survivors but can also occur in human populations via a
homozygous mutation in the Wnt3 gene (Niemann et al.,
2004). Patients with Wnt3 mutations also have facial and
urogenital damage, also seen in some thalidomide survi-
vors. Whether any of the genes associated with these
human genetic conditions are targets of thalidomide to
cause thalidomide-induced embryopathy remains unclear.
The similarity of thalidomide embryopathy to other human
conditions highlights the difficulties faced in diagnosing
conditions. With the advent of genetic testing, many condi-
tions can now be tested for and ruled out.
Another important aspect that helps identify thalido-
mide embryopathy from genetic conditions is that thalido-
mide is not a mutagen and defects are not hereditary, that
is, passed on to the next generation (Ashby et al., 1997;
Ashby and Tinwell, 2002). Indeed a recent study in Swe-
den followed offspring from thalidomide survivors and
found no evidence of any injuries or damage in their off-
spring (Stromland et al., 2002).
Today
The most severely affected children exhibited limb malfor-
mations, facial, genital, and internal organ problems alto-
gether, and the study of the most severely affected
thalidomide babies/children, usually those with bilateral
limb damage (Lenz and Knapp, 1962; Smithells and New-
man, 1992), provided the basis for the diagnostic criteria
used to diagnose thalidomide embryopathy today. How-
ever, patients with less severe damage or, for example, not
exhibiting bilateral limb damage, were excluded. The pre-
cise range and severity of damage this drug caused and
causes may never be known. However, with the ongoing
thalidomide tragedy in Brazil, the thalidomide survivors,
many of whom are children or young adults, offer the pos-
sibility of studying the damage caused and its progression,
FIGURE 2. Time sensitive window of thalidomide embryopathy or the “critical period.” Chart indicating when the major outward appearing damage occurred in
the embryo following thalidomide exposure.
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as well as late onset problems. Furthermore, in early 2014
the World Health Organization hosted a meeting of experts
in thalidomide to re-look at both the diagnostic criteria
and produce a broader range of criteria in light of the Bra-
zil tragedy, and also the increased use of thalidomide
around the world, and to provide guidance on the drug’s
use and contraindications. The new diagnostic algorithm
proposed (www.who-umc.org/graphics/28280.pdf) will
hopefully identify more victims of the drug and help them
get better treatment/therapies.
Part Two: Biochemistry And Mechanisms of Action
Thalidomide was marketed as a nonaddictive, nonbarbitu-
rate sedative that would also be nonlethal if overdoses
occurred (unlike barbiturates; Fig. 1B). The drug is a syn-
thetic derivative of glutamic acid, a naturally occurring
amino acid involved in important physiological processes,
for example, brain neurotransmission and metabolism.
Thalidomide consists of two linked rings, a glutarimide
and pthalimide ring (Fig. 1A). Thalidomide has a chiral
carbon, which is unstable and allows two enantiomers to
coexist, which can interswitch between the two states rap-
idly in bodily fluids and in water (Smith et al., 1965;
Franks et al., 2004). One of the enantiomers is teratogenic,
the S-enantiomer. However as the drug can convert (race-
mise) between enantiomeric states, it is very difficult to
make a stable form that is nonteratogenic. Thalidomide
was sold as a racemic mix of both enantiomers (Fig. 1A)
(Franks et al., 2004).
The parent molecule is believed to have an active half-
life of around 8–12 hr. The drug can be hydrolyzed in bod-
ily fluids and can also be metabolized in the liver by cyto-
chrome p450 enzymes (Fig. 1). The parent molecule is
believed to be the cause of the teratogenesis; however,
many breakdown products are found quickly after admin-
istration (at least 18; Smith et al., 1965; Franks et al.,
2004) and some have been found to be teratogenic in in-
vitro embryo cultures suggesting a combination of parent
molecule and breakdown products cause teratogenesis.
(Lee et al., 2011).
Since thalidomide was banned and withdrawn in 1961/2,
the drug has been discovered to have antiangiogenic, anti-
inflammatory, and anti-myeloma roles. In fact, thalidomide
was found to be useful in treating leprosy as early as 1965
and is now used to treat complications of the condition
around the world (Sheskin, 1965). In 1994, thalidomide was
demonstrated to possess anti-angiogenic actions, which were
suggested could be the cause of thalidomide embryopathy
(D’Amato et al., 1994). Thalidomide is now used to treat some
cancers. Thalidomide has also been demonstrated to be a
potent inhibitor of the inflammatory response, through inhibi-
ting the production of TNF-a (Moreira et al., 1993). Indeed
this action has made the drug very successful for treatments
for conditions including Leprosy and Multiple Myeloma,
Crohns disease, Behcets disease, HIV, lupus, and leprosy.
Mechanisms of Action underlying Thalidomide
Embryopathy
How does thalidomide cause the severe and wide range of
damage in the embryo? The short answer is that it is still
not fully understood. Over 30 separate models/theories
for thalidomide embryopathy have been proposed over the
past 50 years and are reviewed in detail elsewhere, that
include DNA mutagenesis, effects on chrondrogenesis,
nerve/neural crest toxicity, and inhibition of cell adhesion
molecules (Stephens, 1988; Stephens and Fillmore, 2000;
Stephens et al., 2000; Vargesson, 2009, 2013). Some stud-
ies present in vivo evidence and some are hypotheses, and
any valid theory needs to be able to address the time-
sensitive nature of the drug action and the range and vari-
ability of the damage caused.
While these theories are interesting and have some
merits the theories presently widely supported are thali-
domide’s antiangiogenic actions—the drug’s ability to
induce cell death and generate reactive oxygen species
(ROS); the thalidomide binding target, Cereblon, a ubiqui-
tin ligase, which if prevented from binding can reduce tha-
lidomide induced damage in embryos (Stephens, 2009;
Vargesson, 2009, 2013; Ito et al., 2011).
However, these theories are not necessarily mutually
exclusive. Indeed, it is more than likely that all of the pro-
posed theories are involved in some aspect of the cascade
of events that thalidomide induces to cause birth defect.
Moreover, other molecular targets have also recently been
linked to thalidomide embryopathy.
Thalidomide is antiangiogenic
Thalidomide was demonstrated in a landmark study to
inhibit angiogenic vascularization of rodent corneas
induced by fibroblast growth factor (GF) protein (D’Amato
et al., 1994). This discovery led to the suggestion that tha-
lidomide might cause its teratogenic damage by targeting
embryonic blood vessels.
ANGIOGENESIS IS ESSENTIAL FOR EMBRYOGENESIS
Blood vessels are essential for normal embryonic develop-
ment. Blood vessels supply oxygen and nutrients to grow-
ing tissues and remove unwanted waste products. During
embryogenesis, vessels form first by vasculogenesis and
are then modified into the complex vascular tree required
for embryonic and fetal growth and throughout adult life
by angiogenesis (Vargesson, 2003). Angiogenesis is where
the primitive vessels formed by vasculogenesis are elabo-
rated upon where endothelial cells in the existing vessels
proliferate and migrate to avascular areas in response to
signals, including hypoxia or vascular endothelial growth
factor. Once a new vessel tube has been made, the vascular
tube recruits vascular smooth muscle cells, which stabilize
the vessel. The smooth muscle coating is lost to allow
endothelial cells to proliferate and migrate into new
regions if signaled to do so (Vargesson, 2003). Blood
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vessels are rapidly changing throughout embryogenesis
and organogenesis to accommodate the changes and
growth of the embryo.
Blood vessels are essential for normal embryonic devel-
opment, and vessel loss or disruption can unsurprisingly
result in death or birth defect (Vargesson, 2003, 2009).
ANGIOGENESIS IS TARGETED BY THALIDOMIDE IN EMBRYONIC
DEVELOPMENT AND IN THE ADULT
Thalidomide has multiple actions in the adult body and
causes a variety and range of damage in the embryo. To
determine how and which of its activities actually cause
teratogenesis, stable, structural analogs of thalidomide
were screened to determine their function, confirm which
aspect of thalidomide action, antiangiogenesis or antiin-
flammation, results in teratogenesis, and study the result-
ing damage to gain insights into how the drug causes
birth defect (Ng et al., 2003; Franks et al., 2004; Thera-
pontos et al., 2009; Vargesson, 2009; Mahony et al., 2013).
Thalidomide can break down into many byproducts
either hydrolytically or via liver metabolism (Franks et al.,
2004). A range of byproducts of thalidomide, including
CPS49, a tetrafluorinated analog based on 50-OH-
thalidomide, which is one of the breakdown products of
thalidomide and thought to have antiangiogenic activities,
were produced (Price et al., 2002; Ng et al., 2003; Franks
et al., 2004; Vargesson, 2013). Fluorination confers stabil-
ity and increased biological activity onto compounds (Ng
et al., 2003; Franks et al., 2004).
CPS49 was applied over the upper half of the chicken
embryo as limbs are just forming (E2.5; Therapontos
et al., 2009). Blood vessels were rapidly destroyed within
1 hr of exposure in the embryo and several hours before
any changes in limb signaling gene expression and cell
death was observed (Therapontos et al., 2009; Vargesson,
2009, 2013). Reduction in limb area was seen after 6 hr.
After 24 hr, truncated or severely shortened limbs were
observed and in addition, increased cell death was seen,
and loss of FGF (in both the apical ridge and mesenchyme)
and Sonic hedgehog (Shh) signaling was apparent (Fig. 2).
FGF and Shh are key signaling molecules in the developing
limb, controlling patterning and outgrowth (Fig. 3).
Thalidomide has also been reported to cause loss of
FGF and Shh signaling in chick and rabbit embryo limbs
and in zebrafish embryos (Hansen et al., 2002; Ito et al.,
2010; Knobloch et al., 2011). In CPS49 treated chicken
embryos, phocomelia-like limbs were observed 7 days
after just a single exposure (Fig. 4). Just like Thalidomide,
CPS49 acts in a time-sensitive window. Early exposure
resulted in severely truncated limbs, even Amelia, whereas
later exposure caused less severe damage, for example
loss of a digit or digit tips. In fact the damage caused by
CPS49 in chicken embryos was consistent with damage
seen in other studies using thalidomide (Somers, 1962;
Boylen et al., 1963; Merker et al., 1988; Tamilarasan et al.,
2006; Therapontos et al., 2009; Vargesson, 2009, 2013;
Ema et al., 2010).
Similarly, in zebrafish embryos, blood vessels in the
developing spinal cord are stunted and lost rapidly follow-
ing CPS49 treatment. CPS49 was also shown to prevent
Human Umbilical Venous Endothelial Cells (HUVEC) in cul-
ture from proliferating and migrating to form new tubes,
through preventing actin and tubulin cytoskeletal changes
and inhibiting filopodial tip cell formation and migration
(Therapontos et al., 2009).
Studies using CPS49, an antiangiogenic analog of thali-
domide, demonstrated that thalidomide’s antiangiogenic
action can cause its teratogenic actions in a time sensitive
manner (Therapontos et al., 2009).
WHY ARE SOME VESSELS TARGETED WHILE OTHERS ARE APPARENTLY
UNHARMED?
Blood vessels undergoing angiogenesis lose their vascular
smooth muscle coats to allow endothelial cells to
FIGURE 3. Embryonic limb development. Limbs form from a bud from the flanks of the embryo. In humans the upper limbs form around a day earlier (day 26)
than the lower limbs (day 27). The limb bud consists of two key signaling centers. The apical ectodermal ridge (AER), a thickened epithelium lining the distal tip
of the bud and separating the dorsal from ventral surface; and the zone of polarizing activity (ZPA) in the posterior-distal mesenhcyme. The AER expresses Fgf8
which signals to the mesenchyme to induce Fgf10 and to the ZPA to induce and maintain Shh, which itself feeds back to maintain Fgf8. This feedback loop
maintains cell proliferation and limb outgrowth and induces other genes, for example the Hox genes, which establish the pattern of the limb elements, humerus,
radius, ulna, and handplate, as well as the soft tissues. The limbs grow out from specific regions of the flank of the embryo and as the limb grows out the limb is
patterned proximally to distal, that is, humerus/femur are laid down before the radius, ulna/fibular, tibia, and then the handplate/footplate.
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proliferate and migrate to form new tubes (Vargesson,
2003, 2009, 2013). Vessels with smooth muscle coats are
quiescent and not undergoing angiogenesis. Using in-vitro
rat and mouse aortic ring culture assays, CPS49 was dem-
onstrated to destroy vessels without smooth muscle, but
blood vessels possessing smooth muscle coats were pro-
tected (Therapontos et al., 2009). This indicates that newly
formed and forming blood vessels without smooth muscle
coats could be susceptible to thalidomide. In the chicken
embryo at the time the drugs are applied to the embryo,
the developing limb vasculature does not possess smooth
muscle (Vargesson and Laufer, 2001; Therapontos et al.,
2009). In fact, the developing limb does not exhibit
smooth muscle coverage of vessels until quite late in limb
development (Vargesson and Laufer, 2001; Vargesson,
2009, 2013). In contrast to the limb, at the time of expo-
sure (E2.5), the majority of the vessels in the embryo,
including the microvessels in the brain and vessels in the
neck and body, possess smooth muscle coats, intimating
that these vessels are quiescent and protected at this time
FIGURE 4. How does thalidomide induce Phocomelia? Phocomelia is the striking characteristic of thalidomide embryopathy which remains the public image of the
condition and disaster. Phocomelia, the loss of or severe shortening of the limbs long bones, is rarely seen in other conditions. How can thalidomide cause Pho-
comelia? Thalidomide and some of its analogs have been shown to reduce or inhibit FGF (and Shh) expression in developing limbs of rabbits and chickens (Han-
sen et al., 2002; Therapontos et al., 2009; Knobloch et al., 2011). The expression of these genes returns after a few days (Hansen et al., 2002; Knobloch et al.,
2011). Moreover, reduction of FGF signaling in developing mouse limbs can cause phocomelic-like limb injuries through causing increased cell death in proximal
tissues (Mariani et al., 2008). Thalidomide exposure induces cell death in chicken embryo limbs (Knobloch et al., 2007), as does CPS49 an antiangiogenic ana-
log of thalidomide (Therapontos et al., 2009). It has been proposed that thalidomide destroys blood vessels, resulting in cell death and loss of the limb signaling
pathways (Therapontos et al., 2009). The proximal tissue will be lost permanently and unable to be replaced, due to a combination of the limb being unable to
replace the huge number of cells lost, but also the molecular environment in the limb that patterned the proximal elements will no longer be present or be able
to be recapitulated (Mahony and Vargesson, 2013). Recovery or reactivation of FGF signaling could allow the limb to recover, but only distal structures would
form from the remaining tissue, as the tissue is so close to the apical ridge and influenced by distal signals only. Perhaps a misregulation of these signals could
also explain the polydactyly seen in some thalidomide survivors? If the exposure to thalidomide is prolonged or occurred just as the limbs were forming, this could
lead to total vessel loss, widespread cell death, and a complete loss of FGF (and Shh) signaling, which is unable to recover and result in Amelia (no limb).
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(Therapontos et al., 2009; Vargesson, 2009). This observa-
tion correlates well with the range of limb defects seen,
depending on the timing of exposure. Severe defects are
seen after early exposure, but by the time smooth muscle
has appeared on the limb vasculature, defects are
restricted to digits (Therapontos et al., 2009). Further-
more, when the drug was applied to very young embryos
(E1.5), when most tissues are being vascularized and orga-
nogenesis is occurring, embryos died (Therapontos et al.,
2009).
Several nonantiangiogenic analogs and hydrolysis prod-
ucts of thalidomide tested using the same assays were
found to not be teratogenic or obviously harmful to
chicken embryos (Therapontos et al., 2009). This indicates
that the antiangiogenic action of the drug can cause a
wide range of limb defects in a time-dependent manner.
CPS49 in chicken embryos causes loss of vessels before
changes in limb signaling pathways. In zebrafish embryos,
CPS49 causes rapid loss of vessels, which from HUVEC
studies is due to inhibition of actin cytoskeletal dynamics
(Therapontos et al., 2009). Other studies in zebrafish have
demonstrated that thalidomide alters key molecules in
vascular development, including vascular endothelial
growth factor VEGF, a key signaling molecule in vessel
development (Yabu et al., 2005). Another study in zebra-
fish indicates thalidomide may affect gene expression pat-
terns of Shh and Fgf8 before vessels form in developing
fins (Ito et al., 2010). However vascular markers, including
VEGF, were not looked at in this study, and vessels in
other regions of the embryo were not detailed. As zebra-
fish fins and chicken limbs develop and form differently,
this could reaffirm that the drug behaves differently in dif-
ferent species.
Other studies have also demonstrated that blood ves-
sels are targeted and destroyed by thalidomide (D’Amato
et al., 1994; Hallene et al., 2006; Tamilarasan et al., 2006;
Siamwala et al., 2012; Vargesson, 2013). These include
rodent and rabbit corneal assays where blood vessels
induced in response to a FGF soaked bead are destroyed
following thalidomide application (D’Amato et al., 1994;
Kenyon et al., 1997). Rat fetuses exposed to thalidomide in
late gestation show blood vessel disruption in areas of the
brain areas linked to causing autism (Hallene et al., 2006).
Nitric oxide, a molecule required for endothelial cell func-
tion and blood vessel formation, appears to be protective
of blood vessels in chicken embryos. Thalidomide inhibits
nitric oxide expression resulting in vessel loss. Overexpres-
sion of nitric oxide can rescue and/or prevent
thalidomide-induced damage (Tamilarasan et al., 2006;
Majumder et al., 2009; Siamwala et al., 2012). In zebrafish
embryos, thalidomide causes blood vessel defects through
VEGF receptor depletion (Yabu et al., 2005). Thalidomide
has also been shown to successfully treat hereditary hem-
orrhagic telangiectasia (HHT) in human adult patients. The
‘leaky’ vessels seen in this condition are stabilized through
recruitment of smooth muscle and inhibition of angiogene-
sis (Lebrin et al., 2010).
Other antiangiogenic drugs are teratogenic, for exam-
ple, sodium valproate (Whitsel et al. 2002). In addition,
loss of blood vessels in early development is usually lethal
or can cause serious deformity/damage (Vargesson and
Laufer, 2001; Vargesson, 2003, 2009).
Finally, many important molecules involved in embry-
onic vascular development and patterning have been
reported to exhibit changed expression patterns following
thalidomide exposure, for example, actin and tubulin,
integrins, vascular endothelial growth factor, PDGFb, nitric
oxide, ceramide, angiopoietins, Notch, HIF, Slit2/Robo sig-
nalling and ROS (Stephens et al., 2000; Vargesson, 2009,
2013; Feng et al., 2014; Li et al., 2014.)
Taken altogether, the antiangiogenesis mechanism
remains attractive and has a body of evidence supporting it.
Cell death and ROS induction hypothesis
Another attractive hypothesis suggests Thalidomide can
induce formation of ROS, which causes oxidative stress to
cells, which has been proposed to cause limb defects (Par-
man et al., 1999; Hansen and Harris, 2004). By using an
agent that traps and prevents oxidative stress intermedi-
ates, PBN – a-phenyl-N-tertbutylnitrone), it has been dem-
onstrated that following application to rabbits, it
prevented thalidomide induced limb abnormalities in
embryos (Parman et al., 1999) and prevented the forma-
tion of thalidomide hydrolysis products that caused terato-
genesis in rabbit embryo cultures (Lee et al., 2011).
Moreover, expression of Fgf8 and Fgf10 is lost in thalido-
mide treated rabbit embryos, but this effect is reversed
when using the PBN spin trap reagent (Hansen et al.,
2002). Thalidomide exposure can also induce cell death in
limb tissue (Hansen and Harris, 2004; Knobloch et al.,
2007, 2008; Parman et al., 2009; Wells et al., 2009) and
could explain the loss of skeletal elements in the limb, as
well as other damage to tissues in the body. Thalidomide
upregulates bone morphogenetic protein (Bmp) expression
and Dickkopf-1 (Dkk1) expression in the limb, which have
important roles in limb development, among them regulat-
ing cell death (Knobloch et al., 2007). Use of PBN prevents
this thalidomide-induced upregulation and appears to pro-
tect the embryo from thalidomide-induced damage (Kno-
bloch et al., 2007, 2011). Dkk1 is a downstream target of
Bmps and is an antagonist of Wnt, which also regulates
cell survival and proliferation. Thus, induction of oxidative
stress in embryonic tissue can cause thalidomide embry-
opathy through cell death induction (Parman et al., 1999;
Hansen and Harris, 2004; Knobloch et al., 2007, 2008;
Hansen and Harris, 2013). ROS induction also is linked to
causing teratogenesis by other processes, eg maternal dia-
betes (Ornoy et al., 2015) and drugs, for example, ethanol,
phenytoin (Knobloch et al., 2011; Hansen and Harris,
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2013). Furthermore, ROS is required for normal embryo-
genesis in Xenopus and required for Xenopus tadpole tail
regeneration, highlighting the important role ROS play in
normal and causation of abnormal development (Love et
al., 2011; Love et al., 2013). How ROS is involved in these
processes remains unclear. Moreover, how thalidomide
induces the cell death and ROS in specific tissues in a time
sensitive manner and causes the range of damage
observed is unclear. Cell death induction has also been
observed in the forming limb following application of
CPS49, an antiangiogenic analog of thalidomide, and per-
haps inhibition of blood vessels could be a trigger or
involved in induction of ROS and cell death (Therapontos
et al., 2009; Vargesson, 2009).
The possible loss of blood vessels that could cause
stress on cells resulting in cell death locally, and the evi-
dence of the formation of thalidomide-induced ROS in vivo
can prevent/reduce thalidomide induced damage (Parman
et al., 1999; Hansen et al., 2002; Hansen and Harris, 2013;
Knobloch et al., 2007; Lee et al., 2011), suggest that both
mechanisms together could explain much of the damage
and range of damage seen in thalidomide embryopathy.
Other proposed mechanisms of thalidomide-induced
teratogenesis include effects on chrondrogenesis (Stephens
et al., 2000), nerve toxicity/neural crest loss (McCredie
and McBride, 1973), and DNA intercalation (Jonsson,
1972; Hague et al., 2011). All these proposed mechanisms
likely have some involvement; however, in what order? We
know that cartilage loss occurs in thalidomide treated ani-
mals and nerves are missing or changed, but these effects
are likely downstream of the primary action of the drug,
as both these tissues form relatively late in development
(certainly after establishment and outgrowth of the major
tissues including the limbs; Vargesson, 2003, 2013). One
can envisage if tissue/organs are damaged or missing, that
chrondrogenesis and nerve innervation would as a conse-
quence be altered. Moreover, changes in vessel patterns
could have an impact on chrondrogenesis, which requires
a specialized vasculature to allow bone growth and remod-
eling (Kusumbe et al., 2014; Ramasamy et al., 2014).
Indeed, there is evidence, in limbs of human embryos, of a
vascular transition from an embryonic to an adult-like
state around day 45 postconception (59 days after last
menstrual cycle; Hootnick et al., 1980; Levinsohn et al.,
1991; Packard et al., 1991). Moreover, a failure of the
correct transition of the vessel patterns has been pro-
posed to explain a range of human lower limb abnor-
malities, including conditions such as short femur, which
is associated with thalidomide embryopathy (Hamanishi,
1980; Hootnick et al., 1980; Levinsohn et al., 1991;
Packard et al., 1991). Thus, damage to vessels in the
forming limb could prevent or restrict the transition of
the vascular pattern from the embryonic to the adult
state, which could then impact bone formation and
pattern.
Of course the big questions are what is/are the molec-
ular target/s of thalidomide, and how does the drug cause
such wide and ranging embryonic damage? Are there mul-
tiple mechanisms of action and/or targets?
Molecular Targets of Thalidomide
Much is known about thalidomide’s mechanism of action
underlying its anti-inflammatory and anti-myeloma activ-
ities in human adults, than its teratogenic activities. Thali-
domide inhibits TNF-a expression rapidly, vital for the
inflammatory response. However, new targets have been
identified and linked to thalidomide teratogenesis, though
how these targets cause the embryonic damage still
remains unclear.
Cereblon
Cereblon is a candidate gene linked to human mental
retardation (Higgins et al., 2004; Ito et al., 2011). Cereblon
is involved in ubiquitination and forms part of a Cullin4
(Cul4) containing E3 ubiquitination complex with DDB1
(DNA Binding Protein 1) which selects molecules for
destruction (Ito et al., 2010; Ito et al., 2011). Thalidomide
is thought to initiate teratogenesis by binding Cereblon,
which presumably prevents Cereblon from establishing the
E3 ubiquitination complex to target molecules for removal,
causing mis-regulation of developmental signaling mole-
cules (Ito et al., 2010, 2011).
The role of Cereblon in thalidomide’s anti-
inflammatory and antimyeloma response in adults is
much better understood. For example, both Lenalidomide
and Pomalidomide, structural variants of thalidomide
used to treat a range of conditions, also interact with Cer-
eblon and can selectively activate downstream targets
Ikaros and Aiolos to be recruited for degradation and
help mediate their action in multiple myeloma, further
indicating that the anti-tumor and teratogenic actions of
the drug can be dissociated (Kronke et al., 2014; Lu
et al., 2014). Elegant crystal binding structure assays
have shown how thalidomide and Cereblon bind each
other, that the S-enantiomer of thalidomide (and also for
both its related analogs, pomalidomide, and lenalido-
mide) can bind Cereblon, and also demonstrated how
thalidomide can target myeloma cells and target them
through binding Cereblon (Chamberlain et al., 2014;
Fischer et al., 2014). Indeed these studies further suggest
that several targets could be prevented from binding the
E3 ubiquitination complex and thus not be degraded,
including Meis2, a gene involved in proximal limb devel-
opment (Fischer et al., 2014). Cereblon has also been
shown to be able to bind Uridine, an essential component
of the structure of DNA, and Uridine overexposure can
reduce thalidomide-like damage in zebrafish embryos
(Hartmann et al., 2014). A study looking at Cul4a, which
Cereblon interacts with to form the E3 ubiquitination
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complex, suggests in zebrafish that Cul4a may be able to
bind to Tbx5a, a gene involved in pectoral fin (and fore-
limb) and heart development. This study adds to other
studies suggesting that Cereblon following thalidomide
binding could have tissue specific actions by binding tis-
sue specific targets (Zhao et al., 2015). The ability of the
Cereblon complex to induce the degradation of some pro-
teins and prevent the degradation of others can help, at
least in part, explain thalidomide’s varied actions.
However, how Cereblon binding thalidomide actually
results in teratogenesis, causes the range of embryonic
damage and acts in the time-sensitive window of action
remains unclear. Following misexpression of a mutant Cer-
eblon protein that can not bind thalidomide in embryos,
thalidomide induced damage was reduced, which included
Fgf8 expression being maintained (Ito et al., 2010). Several
studies have demonstrated that Fgf8 signaling is reduced
or lost in developing chicken and rabbit limbs, and zebra-
fish fins following thalidomide exposure (Hansen et al.,
2002; Ito et al., 2010; Knobloch et al., 2011). However, it
is unknown if regulation of Fgf8 is directly or indirectly
dependent on Cereblon expression. In addition the expres-
sion pattern of Cereblon in embryonic development is not
fully understood. However, Cereblon knock out mice
appear to be normal and fully functional (Lee et al., 2013).
Altogether these studies demonstrate that Cereblon has
important roles, which include metabolism regulation,
brain development, intellectual ability, inflammatory
response, and teratogenesis. Yet, Cereblon’s precise role in
embryonic development is still unclear and how it can
cause teratogenesis by binding thalidomide is unclear
presently. Moreover, how (or if) thalidomide binding to
Cereblon fits with the drug’s known antiangiogenic and
cell death induction actions is also unclear. It is notewor-
thy that Cereblon has been reported to be expressed in
the developing vasculature of the embryonic zebrafish
head, potentially indicating a link between Cereblon and
the antiangiogenic mechanisms of thalidomide action (Ito
et al., 2010).
Tubulin
An analog of thalidomide, 5HPP-33, can bind tubulin,
which was demonstrated through crystal structure binding
assays (Rashid et al., 2015). Tubulin is part of the cyto-
skeleton, and,is required in cell proliferation, which is
essential for angiogenesis and formation of new vessels in
the embryo. This study demonstrated that tubulin is
bound by the 5HPP-33 thalidomide analog and cytos-
keletal dynamics are altered preventing cell division. In
the time-sensitive window many organs/tissues are under-
going growth and maturation and could be affected in this
manner, either directly or through loss of vessels, resulting
in hypoxia and cell death. This work supports that of other
studies which showed disruption of actin cytoskeleton
dynamics in HUVEC cells following exposure to thalido-
mide (Tamilarasan et al., 2006) and an antiangiogenic ana-
log of thalidomide, CPS49 (Therapontos et al., 2009),
resulting in angiogenesis failure. Thalidomide binding to
tubulin could prevent cell proliferation and migration,
resulting in failed tissue morphogenesis, the severity of
which could be time dependent depending on vascular
and tissue maturation.
Nitric Oxide and Soluble Guanyl Cyclase
Nitric oxide is involved in angiogenesis through stimulat-
ing the production of cGMP via activation of soluble
FIGURE 5. Framework of thalidomide induced embryonic damage. This frame-
work incorporates the majority of the previously proposed models/hypotheses
to attempt to provide an explanation for thalidomide embryopathy. Thalido-
mide and/or a breakdown product after binding a molecular target acts nega-
tively on smooth muscle negative blood vessels, likely affecting the actin
cytoskeleton of the endothelial cells, and preventing their proliferation and
migration into avascular regions, causing oxidative stress, cell death, and
gene expression loss, resulting in tissue damage. In rapidly developing tissues
and organs, such as the limbs and internal organs, this would be devastating,
causing tissue loss or tissue function loss, preventing growth. The damaged or
missing tissues would then also fail to properly recruit and pattern proper
chrondrogenesis, nerve innervation, muscle patterning, etc., exacerbating the
condition and damage.
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Guanyl cyclase. cGMP levels are reduced following thalido-
mide administration, which causes failed angiogenesis in
HUVEC cell cultures (Tamilarasan et al., 2006). When
cGMP levels were increased this prevented thalidomide
induced antiangiogenesis. In silico modelling indicates that
thalidomide can bind soluble Guanyl cyclase (Majumder
et al., 2009). This suggests that thalidomide can affect
embryonic angiogenesis via inhibiting the nitric oxide sig-
naling pathway.
In addition, several studies investigating molecular
changes following thalidomide exposure in monkey fetuses
and in human and mouse embryonic stem cells suggest
changes in as many as 2000 gene expression profiles (Ema
et al., 2010; Meganathan et al., 2012; Gao et al., 2014).
Many of these gene expression profile changes are in
vascular-related and cytoskeletal-related genes.
Summary
Many gene expression changes result from thalidomide
exposure, and seem linked to the vasculature and the cyto-
skeleton. Some binding partners of thalidomide have been
identified, particularly Cereblon, Ikaros, and Aiolos, and
play important roles in mediating thalidomide functions.
Tubulin has been shown to bind a byproduct of thalido-
mide, which could explain the drug’s anti-angiogenic, anti-
proliferative and anti-migratory actions. Moreover, several
molecules have been found to protect against thalidomide-
induced damage in the embryo, including PBN, Nitric
Oxide, Prostaglandin H Synthase and aspirin (Parman et
al., 1999; Majumder et al., 2009; Lee et al., 2011; Arlen
and Wells, 1996). These could act by preventing the par-
ent molecule and/or the teratogenic thalidomide byprod-
ucts being produced or from acting. How these molecular
targets and interactions of thalidomide actually cause and
result in the range of damage seen in thalidomide embry-
opathy is still a matter of debate. Whether there are other
targets of thalidomide, perhaps even tissue specific targets,
also causing teratogenesis, remains an open question.
Conclusions and Challenges
Thalidomide caused a disaster that still shocks the world
today and sadly is happening again in Brazil. Exposure to
the drug during early embryonic development resulted in
severe and a range of damage never seen together before
nor since. Indeed, arguably the most striking damage the
drug caused is phocomelia, which still is not fully under-
stood (Fig. 4). Other damage, such as radial dysplasia,
internal organ damage, and genital injuries can occur in
other syndromes, though, again in the case of radial dys-
plasia, how this comes about in general, let alone in thali-
domide embryopathy, is unclear (Fig. 4). The fact that the
drug has since been found to have many clinical uses, par-
ticularly for the treatment of leprosy and Multiple
Myeloma (amongst others), ensures the drug is still used
today. Yet, can a form of the drug ever be made that
retains clinical effectiveness but not the side effect of birth
defects? To be able to design new drugs for such a pur-
pose, it is essential to understand how the drug caused
the damage and in such a short time window. The mecha-
nisms underlying thalidomide’s teratogenic actions remain
controversial. It is attractive to suggest that the drug tar-
gets multiple tissues through affecting a global process
such as angiogenesis, possibly through affecting the actin
cytoskeleton of rapidly proliferating endothelial cells and
preventing their migration (Fig. 5). This would induce local-
ized reactive species generation and cell death in specific
tissues, and cause tissue damage. What are the targets in
the endothelial cells? Tubulin? Could thalidomide bind spe-
cific types of endothelial cells? Recent work has identified a
new H-endothelial cell type found only in forming bones
(Kusumbe et al., 2014; Ramasamy et al., 2014). Could thali-
domide target tissue specific vessels, causing their loss
through oxidative stress induction, cell death, failed growth,
and loss of signaling? Alternatively, thalidomide could act in
multiple tissues through different, tissue specific mecha-
nisms, which could include antiangiogenesis, induction of
reactive species, and of course through binding Cereblon
and/or other molecular targets, including tubulin (Fig. 5).
Ultimately, both possibilities are attractive and both could
equally explain the severity and the wide range of damage
that thalidomide causes in the embryo.
Despite a resurgence in interest in thalidomide as a
clinical drug, its mechanisms of action to cause teratogene-
sis are still an enigma. However, given the great interest in
thalidomide presently, it will hopefully only be a matter of
time that we finally elucidate the full devastating mecha-
nisms this drug induces.
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